Aileron Therapeutics, Inc. (ALRN, Financial) experienced a significant stock drop of 5.15%, with shares priced at $3.46 and a trading volume of 31,420 shares. The stock's turnover rate was 0.15%, and its amplitude was 3.56%.
Recent financial reports indicate that Aileron Therapeutics achieved zero revenue, incurred a net loss of $8.94 million, and posted an earnings per share (EPS) of -$0.45. The company's gross profit stood at -$4,000, and its price-to-earnings (P/E) ratio was -1.13. Ratings from two institutions unanimously suggest a buy recommendation, with no hold or sell ratings.
Within the biotechnology sector, which saw an overall increase of 0.24%, stocks such as Coeptis Therapeutics Holdings, Inc., Nkgen Biotech, Inc., and Capricor Therapeutics, Inc. showed significant gains. Aditxt, Inc., Gri Bio, Inc., and Seelos Therapeutics, Inc. were highly active, with turnover rates of 148.07%, 49.78%, and 44.38%, respectively. Stocks with substantial amplitude included Tc Biopharm (Holdings) Plc, Capricor Therapeutics, Inc., and Kezar Life Sciences, Inc., with amplitudes of 85.25%, 45.53%, and 39.49%, respectively.
Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and other diseases. Its lead product candidate, ALRN-6924, aims to protect healthy cells in patients with p53-mutant cancers from chemotherapy-induced side effects. The company has two other clinical-stage candidates, LTI-03 and LTI-01, and multiple preclinical candidates targeting fibrosis.
